Abu Dhabi Biobank Joins Forces with Japanese Firm for Stem Cell Advancements

Abu Dhabi Biobank has officially entered into a strategic alliance with Japan's Human Life CORD (HLC), aiming to enhance the development and implementation of umbilical cord–derived stem cell therapies within Abu Dhabi. This endeavor is being backed by the Department of Health – Abu Dhabi (DoH) and global health entity M42.

This partnership signifies a pivotal step in increasing access to state-of-the-art stem cell treatments across the UAE and the broader Middle East and North Africa (MENA) region. Additionally, it fortifies Abu Dhabi’s status as a forerunner in healthcare innovation, life sciences, and precision medicine.

The partnership combines the sophisticated biobanking capabilities and research resources of Abu Dhabi Biobank with HLC’s expertise in mesenchymal stem cell (MSC) technology and clinical innovation. The united goal is to develop personalized regenerative therapies that tackle significant health challenges in the area.

As part of this collaboration, the Department of Health will persist in encouraging research and innovation while promoting public cord blood donation through the biobank. This body will also oversee operational activities to maintain high standards.

In a groundbreaking move for the UAE, this partnership will pave the way for local production and clinical pathways for Umbilical Cord Mesenchymal Stem Cell (UC-MSC) therapies. This will facilitate the comprehensive development of therapies, encompassing everything from the collection of biological samples to their clinical application, all within the country.

Treatments derived from umbilical cords are gaining global recognition due to their potential to diminish inflammation, aid tissue recovery, and safeguard nerve cells. These therapies hold promise for conditions like diabetes, musculoskeletal disorders, and age-related health issues, which are usually addressed by symptom management alone.

Dr. Asma AlMannaei from the Department of Health noted that this partnership signifies a major leap from mere cord blood donation to innovative regenerative medicine. She emphasized that this initiative will promote preventive healthcare and enhance quality of life.

Paul Downey, General Manager of Abu Dhabi Biobank, articulated that this collaboration merges high-quality biological data with real-world treatment development. This connection will be instrumental in translating scientific inquiries into applicable medical solutions.

Masamitsu Harata, CEO of Human Life CORD, expressed confidence that stem cell therapies could revolutionize chronic disease management. He remarked that collaborating with Abu Dhabi Biobank will aid in making these therapies more accessible to patients, leveraging regional health data and local production.

Human Life CORD is already recognized for having multiple stem cell therapies in advanced clinical phases in Japan, leading the way in this sector.

This partnership is part of broader initiatives by Abu Dhabi to advance medical research and innovation while reinforcing scientific partnerships between the UAE and Japan.